Hematologic Oncology

Monotherapy with blinatumomab has demonstrated promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia.

Jennifer A. Woyach, MD, discusses examining the role of BTK inhibition in CLL using murine and cellular models and mechanisms of resistance to BTK inhibitor therapy.

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses a phase I study with an expansion cohort examining the combination of ipilimumab and brentuximab vedotin for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Celgene has entered into a 10-year collaboration with the cellular immunotherapy company Juno Therapeutics, which includes an initial $1 billion payment.

One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.